169 related articles for article (PubMed ID: 38587388)
1. The impact of myelosuppression on quality of life of patients treated with chemotherapy.
Crawford J; Herndon D; Gmitter K; Weiss J
Future Oncol; 2024 Apr; ():. PubMed ID: 38587388
[TBL] [Abstract][Full Text] [Related]
2. New Advances in Supportive Care: Chemoprotective Agents as Novel Opportunities in Geriatric Oncology.
Balducci L; Falandry C; List A
Curr Oncol Rep; 2022 Dec; 24(12):1695-1703. PubMed ID: 35986858
[TBL] [Abstract][Full Text] [Related]
3. Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials.
Ferrarotto R; Anderson I; Medgyasszay B; García-Campelo MR; Edenfield W; Feinstein TM; Johnson JM; Kalmadi S; Lammers PE; Sanchez-Hernandez A; Pritchett Y; Morris SR; Malik RK; Csőszi T
Cancer Med; 2021 Sep; 10(17):5748-5756. PubMed ID: 34405547
[TBL] [Abstract][Full Text] [Related]
4. Real-world burden of chemotherapy-induced myelosuppression in patients with small cell lung cancer: a retrospective analysis of electronic medical data from community cancer care providers.
Epstein RS; Weerasinghe RK; Parrish AS; Krenitsky J; Sanborn RE; Salimi T
J Med Econ; 2022; 25(1):108-118. PubMed ID: 34927520
[TBL] [Abstract][Full Text] [Related]
5. Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States.
Abraham I; Goyal A; Deniz B; Moran D; Chioda M; MacDonald KM; Huang H
J Manag Care Spec Pharm; 2022 Apr; 28(4):435-448. PubMed ID: 35100006
[No Abstract] [Full Text] [Related]
6. Improving Outcomes of Chemotherapy: Established and Novel Options for Myeloprotection in the COVID-19 Era.
Lyman GH; Kuderer NM; Aapro M
Front Oncol; 2021; 11():697908. PubMed ID: 34307165
[TBL] [Abstract][Full Text] [Related]
7. Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy.
Abraham I; Onyekwere U; Deniz B; Moran D; Chioda M; MacDonald K; Huang H
J Med Econ; 2021 Nov; 24(sup1):71-83. PubMed ID: 34873975
[TBL] [Abstract][Full Text] [Related]
8. Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression: Results from an Online Survey of Patients with Solid Tumors.
Epstein RS; Aapro MS; Basu Roy UK; Salimi T; Krenitsky J; Leone-Perkins ML; Girman C; Schlusser C; Crawford J
Adv Ther; 2020 Aug; 37(8):3606-3618. PubMed ID: 32642965
[TBL] [Abstract][Full Text] [Related]
9. Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies.
Weiss J; Goldschmidt J; Andric Z; Dragnev KH; Gwaltney C; Skaltsa K; Pritchett Y; Antal JM; Morris SR; Daniel D
Clin Lung Cancer; 2021 Sep; 22(5):449-460. PubMed ID: 33895103
[TBL] [Abstract][Full Text] [Related]
10. Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study.
Hart LL; Ferrarotto R; Andric ZG; Beck JT; Subramanian J; Radosavljevic DZ; Zaric B; Hanna WT; Aljumaily R; Owonikoko TK; Verhoeven D; Xiao J; Morris SR; Antal JM; Hussein MA
Adv Ther; 2021 Jan; 38(1):350-365. PubMed ID: 33123968
[TBL] [Abstract][Full Text] [Related]
11. Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies.
Hussein M; Maglakelidze M; Richards DA; Sabatini M; Gersten TA; Lerro K; Sinielnikov I; Spira A; Pritchett Y; Antal JM; Malik R; Beck JT
Cancer Manag Res; 2021; 13():6207-6218. PubMed ID: 34408488
[TBL] [Abstract][Full Text] [Related]
12. Critical issues in hematology: anemia, thrombocytopenia, coagulopathy, and blood product transfusions in critically ill patients.
Drews RE
Clin Chest Med; 2003 Dec; 24(4):607-22. PubMed ID: 14710693
[TBL] [Abstract][Full Text] [Related]
13. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of Trilaciclib in preventing chemotherapy-induced myelosuppression: a systematic review and meta-analysis of randomized controlled trials.
Qiu J; Sheng D; Lin F; Jiang P; Shi N
Front Pharmacol; 2023; 14():1157251. PubMed ID: 37305548
[No Abstract] [Full Text] [Related]
15. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial.
Tan AR; Wright GS; Thummala AR; Danso MA; Popovic L; Pluard TJ; Han HS; Vojnović Ž; Vasev N; Ma L; Richards DA; Wilks ST; Milenković D; Yang Z; Antal JM; Morris SR; O'Shaughnessy J
Lancet Oncol; 2019 Nov; 20(11):1587-1601. PubMed ID: 31575503
[TBL] [Abstract][Full Text] [Related]
16. Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer.
Dómine Gómez M; Csőszi T; Jaal J; Kudaba I; Nikolov K; Radosavljevic D; Xiao J; Horton JK; Malik RK; Subramanian J
Int J Cancer; 2021 Oct; 149(7):1463-1472. PubMed ID: 34109630
[TBL] [Abstract][Full Text] [Related]
17. Treatment patterns and burden of myelosuppression for patients with small cell lung cancer: A SEER-medicare study.
Epstein RS; Nelms J; Moran D; Girman C; Huang H; Chioda M
Cancer Treat Res Commun; 2022; 31():100555. PubMed ID: 35421820
[TBL] [Abstract][Full Text] [Related]
18. Burden of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer: A retrospective study from community oncology practices.
Hart L; Ogbonnaya A; Boykin K; Deyoung K; Bailey R; Heritage T; Lopez-Gonzalez L; Huang H; Gordan L
Cancer Med; 2023 Apr; 12(8):10020-10030. PubMed ID: 37000119
[TBL] [Abstract][Full Text] [Related]
19. Managing hematologic toxicities: novel therapies.
Nirenberg A
Cancer Nurs; 2003 Dec; 26(6 Suppl):32S-37S. PubMed ID: 15025411
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]